Adenocarcinoma, Clear Cell clinical trials

The registry lists 46 studies for Adenocarcinoma, Clear Cell across more than 10 countries. 8 are recruiting or about to start. 27 of them are mainly about Adenocarcinoma, Clear Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Adenocarcinoma, Clear Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 23
Recruiting: 8
Active, not recruiting: 8
Status unknown: 4
Withdrawn: 2
Terminated: 1

Phase

Phase 2: 26
Phase 1: 9
Phase 3: 7

Where

United States: 36
Canada: 6
Korea, Republic of: 4
Germany: 3
Hong Kong: 3
Taiwan: 3

Who runs them

Gynecologic Oncology Group (10) · National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (3) · North Eastern German Society of Gynaecological Oncology (2) · Cathay General Hospital (2) · Mayo Clinic (2) · Memorial Sloan Kettering Cancer Center (2) · Centre Oscar Lambret (1)

What is being tested here

Drugs under test in Adenocarcinoma, Clear Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Sacituzumab tirumotecan	1	0	1
Bevacizumab	0	1	3
Nivolumab	0	0	2
Dostarlimab	0	0	1
Ipilimumab	0	0	1
Girentuximab I-124	0	0	1
Gemcitabine	0	1	1
Paclitaxel	0	1	1
Vudalimab	0	0	1
Stem Cell	0	0	1

Drug classes tested here Immune checkpoint inhibitors 4 · Angiogenesis inhibitors 4

Coming up

2phase 3 studies under way

5studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5, phase 3 first

Nov 2026Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer · Phase 3 · University of Utah
Apr 2027Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma · Memorial Sloan Kettering Cancer Center
Apr 2027An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy · University of Texas Southwestern Medical Center
Aug 2027A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) · Yonsei University
Oct 2027A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers · Novartis Pharmaceuticals

Who these studies take

Of the 8 Adenocarcinoma, Clear Cell studies recruiting now, 8 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 2 (25%) take children under 18. 4 (50%) are for women only and 0 (0%) for men only; 1 (13%) take healthy volunteers.

Recruiting studies that take each age, of 8
Age	Women	Men
10	2 (25%)	1 (13%)
18	8 (100%)	4 (50%)
30	8 (100%)	4 (50%)
40	8 (100%)	4 (50%)
50	8 (100%)	4 (50%)
65	8 (100%)	4 (50%)
75	8 (100%)	4 (50%)
85	8 (100%)	4 (50%)

Across all 46 studies, recruiting or not: 4% stop at 75 or younger and 2% at 65; 13% take children; 72% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 46 of 46. search them.